Asset Details
Do you wish to reserve the book?
Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1
Do you wish to request the book?
Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1
2025
Overview
Sirolimus is an effective treatment for acquired pure red cell aplasia (aPRCA), but the detail mechanism of sirolimus on red cell differentiation is incompletely understood. The aim of the study was to investigate whether sirolimus can induce the erythroid differentiation of K562 cells and investigate the potential regulation mechanism. Benzidine staining and flow cytometry were performed to determine the benzidine-/CD71-positive K562 cells with or without sirolimus treatment. The expression level of α-/ γ-globin in each group was determined by real-time qPCR, respectively. siRNA-targeted assays were performed to investigate the role of protein tyrosine phosphatase 1 (SHP1) in sirolimus-induced erythroid differentiation of K562 cells. The proportion of benzidine-staining/CD71-positive cells, and α- / γ-globin mRNA expression were increased in K562 cells treated with sirolimus. Sirolimus markedly inhibited mTOR and p-mTOR expression while upregulated SHP1 expression in K562 cells. Knockdown of SHP1 decrease α-/γ-globin mRNA level, CD71 protein expression levels and the proportion of benzidine-positive cells in the K562 cells. Additionally, knockdown of SHP1 can reverse the sirolimus-induced erythroid differentiation of K562 cells. Sirolimus treatment can promote the erythroid differentiation of K562 cells via upregulating of SHP1.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Cell Differentiation - drug effects
/ Erythroid Cells - drug effects
/ Erythroid Cells - metabolism
/ Humans
/ Medicine
/ Oncology
/ Protein Tyrosine Phosphatase, Non-Receptor Type 6 - biosynthesis
/ Protein Tyrosine Phosphatase, Non-Receptor Type 6 - genetics
/ Proteins
